| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.3 | 0.0 |
| Net income | -93.7 | -80.3 |
| EPS (diluted, $ a share) | $-1.30 | $-1.26 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: VERA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vera Therapeutics, Inc.: key numbers
- Share price
- $26.97Close, Nov 16
- Market cap
- $1.95B
- Shares outstanding
- 72.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vera Therapeutics, Inc.
All →Vera Therapeutics Financial Results
Vera Therapeutics reported its first quarter of commercial revenue following the July 2026 FDA accelerated approval of TRUTAKNA, generating $10.3 million in net product revenue. The company also completed its sBLA submission for full FDA approval and presented positive two-year Phase 3 ORIGIN data demonstrating a 76% reduction in kidney disease progression risk.
- Term
- Q3 2026
“We are excited by the early momentum of the TRUTAKNA launch, which exemplifies our long-standing confidence in its potential to become a foundational therapy in IgAN. Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN.”
Marshall Fordyce, M.D., Founder and Chief Executive Officer
“Our team is executing on the launch priorities we established for TRUTAKNA, with growing interest from the IgAN community and approximately 700 PSFs received since launch. We are encouraged by the payer coverage policies taking shape. Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.”
Matt Skelton, Chief Commercial Officer
Vera Therapeutics Clinical Trial Data
Vera Therapeutics announced positive topline results from the final efficacy analysis of its Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in patients with IgA nephropathy. The trial met all prespecified endpoints, demonstrating a 76% reduction in the risk of kidney disease progression and stabilization of kidney function (eGFR) through 104 weeks. The company plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.
- Term
- 104 weeks